Clinical Trials Logo
  1. Home
  2. Turner Syndrome
  3. NCT01563926
  4. Details
NCT01563926 Clinical Trial

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Turner Syndrome Clinical Trial

Official title:
An Open, Multi-Centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin Simplexx™ in Children With GH Deficiency

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01563926
Other study ID # GHLIQUID-1315
Secondary ID
Status Completed
Phase Phase 3
First received March 23, 2012
Last updated February 23, 2017
Start date October 23, 2000
Est. completion date October 10, 2002

Study information
Verified date February 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

Recruitment information / eligibility
Status Completed
Enrollment 168
Est. completion date October 10, 2002
Est. primary completion date October 10, 2002
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Written Informed Consent by patient and/or guardian/parents

- Patients with one of the following diagnosis: Growth failure due to growth hormone deficiency (GHD), Turner syndrome, or growth retardation in children with chronic renal disorders

- Patients who are willing to inject themselves and answer questionnaires or young patients whose parents/guardian are willing to inject their child and answer questionnaires

- Patients on growth hormone therapy for at least 6 weeks before entering the trial

Exclusion Criteria:

- Pregnancy or breast feeding women

- Suspected or known allergy to trial product

- Other daily injection therapy (non-growth hormone, e.g insulin-therapy)

- Participating in any other trial involving other investigational products within the last 3 months

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• somatropin
Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)

Locations
Country Name City State
Israel Novo Nordisk Investigational Site Afula
Israel Novo Nordisk Investigational Site Beer Sheva
Israel Novo Nordisk Investigational Site Jerusalem
Israel Novo Nordisk Investigational Site Petah Tikva
Israel Novo Nordisk Investigational Site Rehovot
Israel Novo Nordisk Investigational Site Tel - Aviv

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Israel, 

Outcome
Type Measure Description Time frame Safety issue
Primary Patient acceptance of the new liquid growth hormone formulation
Secondary Number of Adverse Events (AE)
Secondary Number of Serious Adverse Events (SAE)
See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01678261 - X-chromosome Inactivation, Epigenetics and the Transcriptome N/A
Completed NCT01419249 - First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Phase 4
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Recruiting NCT04948658 - Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed NCT00877942 - Sex Differences in Early Brain Development; Brain Development in Turner Syndrome N/A
Completed NCT00825617 - Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy N/A
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Enrolling by invitation NCT03836300 - Parent-Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT01322165 - National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions N/A
Terminated NCT00419107 - Beta Cell Function in Women With Turner Syndrome N/A
Active, not recruiting NCT00625001 - Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome N/A
Completed NCT00029159 - The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Phase 3
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Completed NCT00471731 - Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure N/A
Completed NCT00256126 - Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Phase 4
Completed NCT03181230 - Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
Completed NCT02160717 - Risk of Diabetes in Young Turner Syndrome Patients N/A

External Links